How Does The ACCESS Consortium Compare To Project Orbis?
In the second of a two-part interview with the Pink Sheet, an expert from the Swiss drug regulator discusses the similarities and differences between the ACCESS Consortium and Project Orbis, while the Canadian regulator also offers its perspective.
You may also be interested in...
Sixteen cancer therapies have been granted marketing authorizations or label variations in the US this year via the Project Orbis scheme. However, the majority of these are still under review by Orbis partners, which have also been outpaced by the non-Orbis EU.
Regulators from Canada, the UK and Australia discuss their experiences of working together under both the ACCESS Consortium, an international regulatory worksharing coalition, and Project Orbis, a parallel review process designed to speed up access to oncology medicines.
In the first of a two-part interview with the Pink Sheet, an expert from the Swiss drug regulator explains why international collaborations are “the future” and outlines the agency’s “extremely positive” experience since joining the Project Orbis initiative three years ago.